Movilax(Polyethylene Glycol 3350 and electrolytes)
Therapeutic Group: Gastro Intestinal Disorders
Presentation
Movilax Powder for Solution: Each sachet of Movilax contains Polyethylene Glycol 3350 USP-NF13.125 g, Sodium chloride BP 350.7 mg, Sodium Bicarbonate BP 178.5 mg and Potassium Chloride BP 46.6 mg.
Movilax Oral Solution: Each 25 ml concentrated oral solution contains
Polyethylene Glycol 3350 BP- 13.125 g, Sodium Chloride BP- 350.7 mg, Sodium Bicarbonate BP- 178.5 mg, Potassium Chloride BP- 46.6 mg
Description
Polyethylene Glycol 3350 exerts an osmotic action in the gut, which induces a laxative effect. Polyethylene Glycol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. Electrolytes combined with Polyethylene Glycol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in fecal water without net gain or loss of sodium, potassium and water.
Indications
For effective relief from constipation and treatment of chronic constipation. Movilax is also effective in resolving fecal impaction.
Dosage & Administration
For adults and children aged 12 years and above: (Powder for Suspension)
Constipation: The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.
Fecal Impaction:
8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days.
Patients with renal insufficiency:
No dosage change is necessary for treatment of either constipation or fecal impaction.
Direction of use:
Each sachet should be dissolved in 125 ml water. For fecal impaction 8 sachets may be dissolved in 1 litre of water. Store the solution refrigerated and discard any solution not used within 6 hours.
For adults and children aged 12 years and above: Oral Solution
Measure 25 ml of Movilax oral solution with the 25 ml measuring cup provided, then add this to 100 ml of water. Any unused diluted solution should be discarded within 24 hours.
Constipation: 25 ml of Movilax oral solution added to 100 ml of water once daily (to make a total volume of 125 ml). This may be increased to 2-3 doses of 25 ml daily (each 25 ml dose added to 100 ml of water), if required according to individual response.
Fecal Impaction: 8 doses of 25 ml daily (each 25 ml dose added to 100 ml of water). A course of treatment for fecal impaction does not normally exceed 3 days.
Movilax Powder for Solution
Each sachet should be dissolved in 125 ml water. For fecal impaction 8 sachets may be dissolved in 1 litre of water. Store the solution refrigerated and discard any solution not used within 6 hours.
Constipation: The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.
Fecal Impaction: 8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days.
Movilax Oral Solution
Measure 25 ml of Movilax oral solution with the 25 ml measuring cup provided, then add this to 100 ml of water. Any unused diluted solution should be discarded within 24 hours.
Constipation: 25 ml of Movilax oral solution added to 100 ml of water once daily (to make a total volume of 125 ml). This may be increased to 2-3 doses of 25 ml daily (each 25 ml dose added to 100 ml of water), if required according to individual response.
Fecal Impaction: 8 doses of 25 ml daily (each 25 ml dose added to 100 ml of water). A course of treatment for faecal impaction does not normally exceed 3 days.
Side Effects
Generally well tolerated. However side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear.
Precautions
Patients with impaired cardiovascular function: For the treatment of fecal impaction the dose should be divided so that no more than two sachets are taken in any one hour.
If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. edema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Movilax should be stopped immediately and any abnormality should be treated appropriately.
Prolonged use with all laxatives is undesirable and may lead to dependence.
Use in Pregnancy & Lactation
Use in Pregnancy:
There is no experience of the use of Polyethylene Glycol 3350 during pregnancy and lactation. It should only be used if considered essential by the physician.
Use in Lactation:
It is unknown whether Polyethylene Glycol 3350 is excreted in human breast milk.
Drug Interaction
No specific drug interactions have been found.
Over Dose
Severe pain or distention can be treated by nasogastric aspiration. Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.
Commercial Pack
Movilax Powder for Solution: Each box contains 10 Alu-Alu sachets of powder for solution.
Movilax Oral Solution: Each box contains 100 ml concentrated oral solution in HDPE bottle with a measuring cup.
Movilax Powder for Solution: Each box contains 10 Alu-Alu sachets of powder for solution.
Movilax Oral Solution: Each box contains 100 ml concentrated oral solution in HDPE bottle with a measuring cup.
Therapeutic Group: Gastro Intestinal Disorders
Presentation
Movilax Powder for Solution: Each sachet of Movilax contains Polyethylene Glycol 3350 USP-NF13.125 g, Sodium chloride BP 350.7 mg, Sodium Bicarbonate BP 178.5 mg and Potassium Chloride BP 46.6 mg.
Movilax Oral Solution: Each 25 ml concentrated oral solution contains
Polyethylene Glycol 3350 BP- 13.125 g, Sodium Chloride BP- 350.7 mg, Sodium Bicarbonate BP- 178.5 mg, Potassium Chloride BP- 46.6 mg
Description
Polyethylene Glycol 3350 exerts an osmotic action in the gut, which induces a laxative effect. Polyethylene Glycol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. Electrolytes combined with Polyethylene Glycol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in fecal water without net gain or loss of sodium, potassium and water.
Indications
For effective relief from constipation and treatment of chronic constipation. Movilax is also effective in resolving fecal impaction.
Dosage & Administration
For adults and children aged 12 years and above: (Powder for Suspension)
Constipation: The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.
Fecal Impaction:
8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days.
Patients with renal insufficiency:
No dosage change is necessary for treatment of either constipation or fecal impaction.
Direction of use:
Each sachet should be dissolved in 125 ml water. For fecal impaction 8 sachets may be dissolved in 1 litre of water. Store the solution refrigerated and discard any solution not used within 6 hours.
For adults and children aged 12 years and above: Oral Solution
Measure 25 ml of Movilax oral solution with the 25 ml measuring cup provided, then add this to 100 ml of water. Any unused diluted solution should be discarded within 24 hours.
Constipation: 25 ml of Movilax oral solution added to 100 ml of water once daily (to make a total volume of 125 ml). This may be increased to 2-3 doses of 25 ml daily (each 25 ml dose added to 100 ml of water), if required according to individual response.
Fecal Impaction: 8 doses of 25 ml daily (each 25 ml dose added to 100 ml of water). A course of treatment for fecal impaction does not normally exceed 3 days.
Movilax Powder for Solution
Each sachet should be dissolved in 125 ml water. For fecal impaction 8 sachets may be dissolved in 1 litre of water. Store the solution refrigerated and discard any solution not used within 6 hours.
Constipation: The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.
Fecal Impaction: 8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days.
Movilax Oral Solution
Measure 25 ml of Movilax oral solution with the 25 ml measuring cup provided, then add this to 100 ml of water. Any unused diluted solution should be discarded within 24 hours.
Constipation: 25 ml of Movilax oral solution added to 100 ml of water once daily (to make a total volume of 125 ml). This may be increased to 2-3 doses of 25 ml daily (each 25 ml dose added to 100 ml of water), if required according to individual response.
Fecal Impaction: 8 doses of 25 ml daily (each 25 ml dose added to 100 ml of water). A course of treatment for faecal impaction does not normally exceed 3 days.
Side Effects
Generally well tolerated. However side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear.
Precautions
Patients with impaired cardiovascular function: For the treatment of fecal impaction the dose should be divided so that no more than two sachets are taken in any one hour.
If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. edema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Movilax should be stopped immediately and any abnormality should be treated appropriately.
Prolonged use with all laxatives is undesirable and may lead to dependence.
Use in Pregnancy & Lactation
Use in Pregnancy:
There is no experience of the use of Polyethylene Glycol 3350 during pregnancy and lactation. It should only be used if considered essential by the physician.
Use in Lactation:
It is unknown whether Polyethylene Glycol 3350 is excreted in human breast milk.
Drug Interaction
No specific drug interactions have been found.
Over Dose
Severe pain or distention can be treated by nasogastric aspiration. Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.
Commercial Pack
Movilax Powder for Solution: Each box contains 10 Alu-Alu sachets of powder for solution.
Movilax Oral Solution: Each box contains 100 ml concentrated oral solution in HDPE bottle with a measuring cup.
Movilax Powder for Solution: Each box contains 10 Alu-Alu sachets of powder for solution.
Movilax Oral Solution: Each box contains 100 ml concentrated oral solution in HDPE bottle with a measuring cup.